Abstract
We report the presence of the second human pegivirus (HPgV-2) in Guangdong and Sichuan Provinces in China. The prevalence of HPgV-2 in hepatitis C virus/HIV-1–co-infected persons who inject drugs was 12.9% in Guangdong and 15.9% in Sichuan. This population is at high risk for HPgV-2 infection.
Highlights
We report the presence of the second human pegivirus (HPgV-2) in Guangdong and Sichuan Provinces in China
We observed a statistically significant difference between HIV1–positive/hepatitis C virus (HCV)-positive patients and HIV-1–positive/ HCV-negative patients in the prevalence of having HPgV2 antibodies (10% vs. 0; p
Previous reports, we found that the prevalence of HPgV viremia was 7.9% in HCV and HIV-1–negative men who have sex with men (MSM) and 33.3%–40% in HCV/HIV-1 co-infected MSM and persons who inject drugs (PWID) (Table 1)
Summary
Other reports [1,2,3]. Phylogenetic analysis indicated that HPgV-2 strains from China, the United States, and the United Kingdom clustered together to form a separate branch and fell into group 1 with the closely related pegiviruses from bats and rodents (Figure 2). Other pegiviruses from human, simian, and equine sources formed group 2, in which the variants of HPgV fell into a separate clade. Previous reports, we found that the prevalence of HPgV viremia was 7.9% in HCV and HIV-1–negative MSM and 33.3%–40% in HCV/HIV-1 co-infected MSM and PWID (Table 1). Only 0.5% of MSM and 0.4% of healthy blood donors were positive for HPgV-2 antibodies, but all were negative for HPgV-2 RNA (Table 1). These results indicate that HPgV-2 infection might be much less frequent than HPgV infection, possibly because of its low transmissibility or high clearance rate [2,3,4]. HPgV does not cause human diseases [11] and can inhibit HIV-1 replication as well as prolong survival of
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
